The United States Patent and Trademark Office has issued US Patent 9,248,076 B2, titled “Dose Dispensing Containers,” to Mystic Pharmaceuticals, the company has announced. The patent covers nose-to-brain delivery systems for therapies to treat brain disorders such as Alzheimer’s disease and traumatic brain injury using Mystic’s VersiDoser and VRx2 blister packaging and delivery technology.
Mystic Founder Timothy Sullivan commented, “Nose to brain delivery is emerging as a viable means of non-invasive delivery of certain classes of drugs and biologics directly into the brain via the nose, while bypassing the blood brain barrier. Our long-term vision is the development of patient-centric drug/device combination products that can safely and effectively be used directly by patients and caregivers to self-administer therapeutics for treating neurodegenerative diseases.”
Read the Mystic Pharmaceuticals press release.
